Case Report: Ivonescimab in EGFR-mutant lung cancer with baseline malignant pleural effusion and acquired complex resistance
This case illustrates the potential benefit of ivonescimab in patients with EGFR-mutant LUAD and baseline MPE who develop complex, non-canonical resistance to EGFR-TKIs. These findings support further clinical evaluation of ivonescimab in this poor-prognosis subgroup and highlight the importance of repeated molecular profiling in guiding treatment strategy.
Authors
- Zeming Mo (ORCID: https://orcid.org/0000-0002-0476-7618)
- Lei Zhou (ORCID: https://orcid.org/0000-0003-0417-1168)
- Lie Li (ORCID: https://orcid.org/0000-0003-1508-5484)
- Gang Shen
- Yuju Bai (ORCID: https://orcid.org/0000-0003-2897-9997)
- Qiaoya Ren
- Mi Meng
- Hua Yang
- Sisi He (ORCID: https://orcid.org/0000-0002-1492-0532)
- Han Jiang (ORCID: https://orcid.org/0000-0001-7242-3369)
- Xiaobin Jian
Institutions
- Zunyi Medical University (CN)
- Affiliated Hospital of Zunyi Medical College (CN)
- Qiannan Normal College For Nationalities (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-17
- DOI
- https://doi.org/10.3389/fimmu.2025.1725067
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Health Commission of Guizhou Province